Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 29581132.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0380.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The immune response is a dynamic multistep process with a complex system regulation. Identification of predictive biomarkers is therefore challenging. Deep investigation of an exceptional responder to pembrolizumab in ovarian cancer identifies a new mechanism of response and highlights the interest of individualized medicine strategy. <i>Clin Cancer Res; 24(14); 3233-5. ©2018 AACR</i><i>See related article by Bellone et al., p. 3282</i>.
Medical subject headings
- B7-H1 Antigen
- Ovarian Neoplasms